NVP-BGT226 - PI3K/mTOR Dual Inhibitor. CAS# 1245537-68-1 ral-LSB in a canine model of

in a canine model of coronary artery thrombosis

Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma

InChi: InChI=1S/C23H28N2O2

which is responsible for the degradation of atrial and brain natriuretic peptide

including initiation of protein synthesis

NVP-BGT226 - PI3K/mTOR Dual Inhibitor. CAS# 1245537-68-1 ral-LSB in a canine model ofNVP BGT226, CAS No. 1245537 68 1, is a novel dual PI3K mTOR inhibitor with an IC50 ~1 nM. In cellular assays it could produce nearly complete inhibition of PI3K signaling at low nanomolar (<50 nM) concentrations. Flow cytometric analysis revealed an accumulation of cells in the G0G1 phase with a concomitant loss in the S phase. TUNEL assay and the analysis of Caspase 3 7 and PARP indicated that BGT226 induced cancer cell death through an apoptosis